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S U M M A R Y
Objectives: Dientamoeba fragilis is a pathogenic protozoan of the human gastrointestinal tract with a
worldwide distribution, which has emerged as an important and misdiagnosed cause of chronic
gastrointestinal illnesses such as diarrhea and ‘irritable-bowel-like’ gastrointestinal disease. Very little
research has been conducted on the use of suitable antimicrobial compounds. Furthermore, higher rates
of co-infection with Enterobius vermicularis have been described, suggesting that E. vermicularis could
inﬂuence the treatment of D. fragilis-infected patients. To study this, the treatment of E. vermicularis and
D. fragilis co-infected patients was evaluated.
Methods: Forty-nine patients with a D. fragilis infection, including 25 (51.0%) patients co-infected with E.
vermicularis, were studied. All of them were treated with metronidazole. Patients with E. vermicularis co-
infection and/or an E. vermicularis-positive case in the family were treated with mebendazole.
Results: Metronidazole treatment failure was signiﬁcantly more frequent in patients with E. vermicularis
co-infection and in patients with children in the family.
Conclusions: Co-infection with E. vermicularis may act as a factor favoring D. fragilis infection by
preventing eradication measures. This suggests that both parasites should be treated simultaneously.
 2016 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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jou r nal h o mep ag e: w ww .e lsev ier . co m / loc ate / i j id1. Introduction
Dientamoeba fragilis is a pathogenic protozoan of the human
gastrointestinal tract with a worldwide distribution. It has
emerged as an important and misdiagnosed cause of chronic
gastrointestinal illnesses such as diarrhea and ‘irritable-bowel-
like’ gastrointestinal disease.1,2 Higher rates of co-infection with
Enterobius vermicularis have been described in previous papers.3,4
Despite the growing importance of this parasite, very little
research has been conducted on the use of suitable antimicrobial
compounds. Recently, a randomized trial was performed to
evaluate the efﬁcacy of metronidazole in children, with negative
conclusions.5 The inﬂuence of E. vermicularis and its treatment* Corresponding author. Tel.: +34 985108000 (39177).
E-mail address: azucenarodriguez@telecable.es (A. Rodrı´guez-Guardado).
http://dx.doi.org/10.1016/j.ijid.2016.05.027
1201-9712/ 2016 The Authors. Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).with regard to the usefulness of metronidazole was evaluated in
this study.
2. Methods
A standard protocol for the screening of imported diseases is used
routinely in all individuals who attend the study unit for the ﬁrst time,
regardless of race, sex, origin, and symptomatology. All individuals
who were found to be infected by D. fragilis between January 2012 and
January 2014, as well as their infected household contacts, were
enrolled in this retrospective, descriptive study. This research is part of
an overall project entitled ‘‘Usefulness of molecular diagnosis
techniques in parasitology’’ validated and approved by the Ethics
Committee of Clinical Investigation of Asturias (Spain).
Each patient’s clinical history, including diarrhea within the
preceding 3 months, nature of the diarrhea, abdominal pain,
intensity of fever, nausea and/or vomiting, urticaria, anal pruritus,ciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
Table 1
Characteristics of patients who were cured and patients who were not cured
Parameter Cured n = 43 Not cured n = 6 p-Value OR (95% CI )
Demographic characteristics
Sex (M/F) 22/21 4/2 0.395 NS
Age, years (Standard Deviation) 30 (21) 27 (17) 0.421 NS
Age under 14 years 15/28 3/3 0.656 NS
Children under 14 in family (yes/no) 26/17 6/0 0.065 1.231 (1.042–1.454)
E. vermicularis detection
Co-infected by E. vermicularis (yes/no) 19/24 6/0 0.013 1.316 (1.056–33.29)
Relative with E. vermicularis (yes/no) 27/16 6/0 0.079 1.222 (1.041–1.435)
Asymptomatic (yes/no) 23/20 6/0 0.034 1.261 (1.047–1.518)
OR, odds ratio; CI, conﬁdence interval; M, male; F, female; NS, not signiﬁcant.
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least three unformed or liquid stools per day for at least 3 days.
Treatment history also included anti-parasitic drugs.
Blood tests and biochemical analyses, including liver enzyme
levels, were performed for all patients. Eosinophilia was deﬁned as
>0.5  109 eosinophils/l .
Three stool samples per patient were concentrated using a
Copropack Extraction Kit C100 (Cromakit S.L., Spain), following the
manufacturer’s instructions. These were then stained with lugol and
screened under a light microscope with a low magniﬁcation to detect
helminth eggs, protozoa trophozoites, and cysts. An immunoﬂuores-
cence test (MERIFLUOR Cryptosporidium/Giardia kit; Meridian
Bioscience, USA) was performed using concentrated stool samples
to detect Cryptosporidium spp and Giardia lamblia. Genome detection
of D. fragilis as well as Entamoeba histolytica and Entamoeba dispar was
performed in stool samples following previous extraction with a
QIAamp DNA Stool Mini Kit (Qiagen, Netherlands), using two
methods based on PCR, as described previously.6,7
A pinworm test was performed in stool samples of all patients
with D. fragilis. Thus, pinworm eggs or a few adult worms that had
adhered to a piece of transparent cellophane tape applied to the
anal region on two consecutive mornings immediately after the
infected person woke up and before any bowel movement or
cleansing (bath or shower), were identiﬁed by examination under a
microscope.
Parasitological controls were performed at 4 and 8 weeks after
the end of treatment in all patients. Patients who failed to deliver
one or more pieces of cellophane tape or stool samples, or who had
received anti-parasitic treatment in the previous 6 months, or who
were infected by other parasites different to E. vermicularis were
excluded.
All patients were treated with metronidazole 500 mg/8 h (25–
35 mg/kg/day in three doses in children). Patients with E.
vermicularis co-infection and/or an E. vermicularis-positive case in
the family were treated with mebendazole 100 mg/12 h for 3 days.
Qualitative variables were compared using the Chi-square test,
or Fisher’s exact test, when necessary. For quantitative variables,
the Student t-test for non-paired variables or the Mann–Whitney
U-test was used. Signiﬁcance was set at p < 0.05. Multivariate
analysis was performed using logistic regression (enter method) to
identify variables that showed an independent association with
treatment failure. The variables included in the model were those
with a statistically signiﬁcant association (p < 0.05) in the
bivariate analysis. All tests were performed using SPSS for
Windows version 15 software (SPSS Inc., Chicago, IL, USA).
3. Results
Forty-nine patients were studied and treated. Fifty-three
percent of them were male. The mean age was 30 years (range
3–71 years). Eighteen patients were under 14 years of age. Most of
them were from Spain (65.3%), followed by Equatorial Guinea(12.2%), Pakistan (10.2%), Colombia (8.2%), and Paraguay (4.1%). In
immigrant patients, the average time of permanent residence in
Spain prior to the ﬁrst consultation was 853  540 days and no
patient had travelled to their country of origin in the last year.
Twenty-nine patients (59.2%) were asymptomatic. For the remaining
patients, the most frequent symptoms were abdominal pain
(10 patients) and diarrhea (three patients). Only one patient
described anal pruritus. Twenty-seven patients (55%) had hyper-
eosinophilia in the blood and 17 of them were asymptomatic. The
mean level of eosinophilia was 1.361  1.676  109 cells/l. Twenty-
ﬁve (51%) patients had a co-infection with E. vermicularis, 64% of them
being children under 14 years of age.
All were treated with metronidazole, with a cure rate of 87.8%.
Thus, 43 patients had complete resolution of symptoms and a
normalization of eosinophil levels. Nevertheless, six patients
showed a persistence of D. fragilis in control stool samples taken
4 weeks after the treatment. No differences in sex or age between
the patients who were cured and not cured were found. No
signiﬁcant differences were found after studying whether
age < 14 years was associated with treatment failure (3 vs. 3,
p = 0.656). Treatment failure was signiﬁcantly more frequent in
patients with E. vermicularis co-infection (6 vs. 0, odds ratio (OR)
1.316 (95% conﬁdence interval (CI) 1.056–1.454), p = 0.013) and
nearly signiﬁcant in those with a child in the family (6 vs. 0, OR
1.231 (95% CI 1.042–1.454), p = 0.065 ). All patients with treatment
failure were asymptomatic (Table 1).
A second treatment with paromomycin (25–35 mg/kg/day,
usually divided into three doses, for 5–10 days) was administered
to the six patients with no response to metronidazole. A
parasitological control test was performed in all of these patients
with negative results at 4 and 8 weeks after the end of treatment,
indicating that all of them had responded to it.
4. Discussion
Dientamoeba fragilis is a trichomonad parasite, which has been
described as a cause of gastrointestinal disease. Although several
reports support the efﬁcacy of metronidazole for the treatment of
D. fragilis infection, others have reported treatment failures and
relapses. Preiss et al. administered metronidazole (30 mg/kg/day
for 10 days) to children and this was found to be effective in 70% of
the cases. The remaining 30% of cases required up to three follow-
up treatments for complete resolution of parasites and symptoms.8
Vandenberg et al. reported parasitological and clinical cure in eight
out of 12 patients, although no dosage information was given.9
Although Stark et al. reported a similar cure rate to that found in
the present study (80% of cases), a relatively high rate of treatment
failures/relapses (21.4%) was associated with the use of metroni-
dazole. The majority of treatment failures were associated with a
3-day course of metronidazole and these were less likely with a
longer duration of therapy.1
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although eradication of D. fragilis was signiﬁcantly greater in a
group of metronidazole-treated infected patients than in a group of
placebo-treated infected patients, it declined rapidly from 2 weeks
to 8 weeks after the end of treatment (62.5% and 24.9%,
respectively). These data do not support the routine use of
metronidazole for the treatment of D. fragilis-positive children
with chronic gastrointestinal symptoms.5 In this trial, a pinworm
prevalence of 24% and a relative risk of 1.20 (95% CI 1.01–1.44) for
post-treatment D. fragilis infection when the subject was
pinworm-positive were reported. Higher pinworm prevalence
(51%) and a similar relative risk were observed in the present
study, where all patients with E. vermicularis infection were treated
with mebendazole and the parasite was eradicated at 4 and
8 weeks after the end of treatment.
E. vermicularis has been associated with the transmission of D.
fragilis due to the higher rates of co-infection described in several
studies, as well as the isolation of D. fragilis DNA on the surface of E.
vermicularis eggs.3,4 The present results support the hypothesis
that co-infection with E. vermicularis may act as a factor favoring D.
fragilis infection by preventing eradication measures. This suggests
that both parasites should be treated simultaneously. The fact that
E. vermicularis is a common parasite in the child population
explains why treatment failures are more common in this age
group.
Further research is necessary to evaluate the role of the
association of D. fragilis and E. vermicularis when choosing a
treatment and whether the use of mebendazole improves the
treatment of D. fragilis infection.Ethical approval: This work was approved by the Ethics
Committee of the Hospital Universitario Central de Asturias.
Conﬂict of interest: All authors state that there are no ﬁnancial or
personal relationships with other people or organizations that
could inappropriately have inﬂuenced (biased) their work. This
study was not funded by any source.
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